Key result
PCI evolves toward DES and emerging non-stent strategies to address very late stent thrombosis.
Why the study?
To review the historical development and future perspective of PCI, especially focusing on the evolution of DES and emerging non-stent strategies to address complications like very late stent thrombosis.
This review highlights the evolution of PCI technology from balloon angioplasty to drug-eluting stents, emphasizing the ongoing need to address complications like very late stent thrombosis through novel stent designs and non-stent strategies.
Supports development of non-stent options; leaves open optimal strategies to reduce very late thrombosis.
Percutaneous coronary intervention (PCI) using balloon technology and stent implantation has revolutionized the interventional cardiology since the late 1970s. The plane old balloon angioplasty (POBA) was first proposed in the late 1970s as an alternative to coronary artery bypass grafting (CABG) for the treatment of coronary artery disease (CAD) such as angina pectoris and acute myocardial infarction (AMI). Thereafter, bare metal stent (BMS) was designed to overcome the problems proposed by POBA such as acute occlusion and restenosis of coronary target lesion. However, a new problem of BMS-induced in-stent restenosis (ISR) has appeared, and drug-eluting stent (DES) was introduced to resolve the problem of ISR. DES has improved the clinical outcome of patients undergoing PCI. Contemporary stent technology shows remarkable progress, and further effort continues to improve the design, structure, and materials of DES. However, DES has proposed a new problem of very late stent thrombosis. To overcome this late complication, non-stent strategy is introduced into the PCI. This article aims to review the historical development and future perspective of the PCI especially focusing on the evolution of DES.
No takes yet. Share an insight, caveat, or question.
Nakaji et al. (2022) conducted a review in Coronary artery disease (CAD). Percutaneous coronary intervention (PCI) and coronary stents was evaluated. Percutaneous coronary intervention and stent technology have evolved from balloon angioplasty to drug-eluting stents, with non-stent strategies emerging to address very late stent thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: